Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 986,300 shares, an increase of 22.9% from the November 30th total of 802,800 shares. Approximately 1.7% of the shares of the stock are short sold. Based on an average daily volume of 525,700 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Investors Weigh In On Context Therapeutics

A number of institutional investors have recently made changes to their positions in CNTX. Great Point Partners LLC acquired a new position in Context Therapeutics in the second quarter valued at $14,876,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the 2nd quarter valued at about $10,348,000. Driehaus Capital Management LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter valued at about $4,527,000. Nantahala Capital Management LLC acquired a new stake in Context Therapeutics during the second quarter worth approximately $3,881,000. Finally, Ally Bridge Group NY LLC increased its holdings in Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Trading Down 0.5 %

Context Therapeutics stock traded down $0.01 during mid-day trading on Tuesday, reaching $1.06. The company had a trading volume of 1,433,842 shares, compared to its average volume of 363,410. The business has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $1.98. The company has a market cap of $79.12 million, a P/E ratio of -1.16 and a beta of 2.00. Context Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Research analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on CNTX shares. D. Boral Capital initiated coverage on shares of Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $6.80.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.